Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The Company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. Sanifit’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study in hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease (PAD) in patients with end-stage kidney disease as a second indication for SNF472.
For more information, please visit www.sanifit.com.
For further enquiries:
Joan Perelló, Ph.D., CEO / Adam Levy, CFO
For media enquiries:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700